Healthcare -
Drug Manufacturers - General - NYSE - US
$ 14.695
1.27 %
$ 3.79 B
Market Cap
4.41
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Organon & Co.
| Revenue | 6.4 B |
| Cost Of Revenue | 2.69 B |
| Gross Profit | 3.72 B |
| Operating Expenses | 2.23 B |
| Operating Income | 1.49 B |
| Other Expenses | 622 M |
| Net Income | 864 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Revenue | 6 403.0 | 6 263.0 | 6 174.0 | 6 304.0 | 8 096.0 | 7 777.0 | 9 777.0 | 10 500.0 |
| GROSS PROFIT | ||||||||
| Cost Of Revenue | 2 688.0 | 2 515.0 | 2 294.0 | 2 382.0 | 3 347.0 | 2 274.0 | 4 693.0 | 4 588.0 |
| Gross Profit | 3 715.0 | 3 748.0 | 3 880.0 | 3 922.0 | 4 749.0 | 5 503.0 | 5 084.0 | 5 912.0 |
| OPERATING INCOME | ||||||||
| Operating Expenses | 2 229.0 | 2 421.0 | 2 175.0 | 2 111.0 | 1 970.0 | 1 663.0 | 2 378.0 | 2 640.0 |
| Selling, General and Administrative Expenses | 1 760.0 | 1 893.0 | 1 704.0 | 1 668.0 | 1 666.0 | 1 443.0 | 2 013.0 | 2 285.0 |
| Research and Development Expenses | 469.0 | 528.0 | 471.0 | 443.0 | 304.0 | 220.0 | 365.0 | 355.0 |
| Operating Income | 1 486.0 | 1 327.0 | 1 478.0 | 1 619.0 | 2 849.0 | 3 847.0 | 2 706.0 | 3 272.0 |
| PRE-TAX INCOME | ||||||||
| Interest Income Expense | 520.0 | 527.0 | 422.0 | 258.0 | 6.0 | 6.0 | 0 | 0 |
| Total Other Income | (679.0) | (654.0) | (583.0) | (386.0) | (95.0) | (144.0) | 23.0 | (173.0) |
| Pre-Tax Income | 807.0 | 673.0 | 1 122.0 | 1 529.0 | 2 680.0 | 3 696.0 | 2 729.0 | 3 099.0 |
| NET INCOME | ||||||||
| Tax Provision | (57.0) | (350.0) | 205.0 | 178.0 | 520.0 | 390.0 | 576.0 | 1 298.0 |
| Net Income | 864.0 | 1 023.0 | 917.0 | 1 351.0 | 2 160.0 | 3 218.0 | 2 153.0 | 1 801.0 |
| EPS | 3.36 | 4.01 | 3.61 | 5.33 | 8.52 | 12.7 | 8.51 | 7.11 |